肝脂肪变性对慢性乙型肝炎进展的影响：前瞻性队列和体外

StephenW

Oncotarget. 2017 Apr 24. doi: 10.18632/oncotarget.17380. [Epub ahead of print]
Effect of hepatic steatosis on the progression of chronic hepatitis B: A prospective cohort and in vitro study.
Chen Y1, Fan C1, Chen Y1, Liu H2, Wang S1,3, Dong P1, Li L1, Ding H1.
Author information

1    Department of Gastroenterology and Hepatology, Beijing You'an Hospital affiliated with Capital Medical University, Beijing 100069, China.
2    Department of pathology, Beijing You'an Hospital affiliated with Capital Medical University, Beijing 100069, China.
3    Beijing Institute of Hepatology, Beijing 100069, China.

Abstract
AIM:

To characterize the effect of hepatic steatosis (HS) on the progression of chronic hepatitis B.
METHODS:

A total of 162 chronic hepatitis B (CHB) patients confirmed by liver biopsy were involved in this study. All subjects were prospectively followed-up for 5 years in real-life clinical practice. Fibrosis stage was determined using aspartate aminotransferase-to-platelet ratio index (APRI). The end-point was cirrhosis, liver cancer or death. The effects of steatosis on the biological behavior of hepatocellular carcinoma cells were investigated using oleic acid-induced lipid accumulation in HepG2, HLE, PLC, and SMMC-7721 cells.
RESULTS:

Mean age, body mass index, and serum cholesterol were significantly higher in CHB patients with HS than those without HS at baseline (p< 0.05). The APRI was lower in patients without HS at baseline (p<0.05). Compared to patients with HS, APRI of patients without HS decreased significantly during the follow-up period (p<0.05). The 5-year cumulative incidence of cirrhosis were 4.17% and 5.19% in patients without and with HS, respectively (p>0.05). The multivariate analysis showed that older (RR 1.07, 95% CI 0.996-1.149, p = 0.065) and S3 stage of liver fibrosis (RR 3.50, 95% CI 0.812-15.117, p=0.093) were risk factors for the progression to cirrhosis. In vitro, cell steatosis promoted proliferation and migration of HCC cells and conferred cell cycle at S phase.
CONCLUSION:

The older and S3 stage of fibrosis may be risk factors for progression to cirrhosis in CHB patients with HS. HS may aggravate liver disease, promoting HCC progression.
KEYWORDS:

chronic hepatitis B; hepatic steatosis; hepatocellular carcinoma cells

PMID:
    28500841
DOI:
    10.18632/oncotarget.17380

Free full text

StephenW

Oncotarget。 2017年4月24日。doi：10.18632 / oncotarget.17380。 [提前印刷]
肝脂肪变性对慢性乙型肝炎进展的影响：前瞻性队列和体外研究。
陈毅，范Fan，陈Y1，刘H2，王Wang，，董P1，李，丁丁。
作者信息

1首都医科大学附属北京友安医院消化内科，北京100069。
2首都医科大学附属北京友安医院病理科北京100069。
3北京肝脏病研究所，北京100069。

抽象
目标：

描述肝脂肪变性（HS）对慢性乙型肝炎进展的影响。
方法：

本研究共纳入162例肝活检证实的慢性乙型肝炎（CHB）患者。所有受试者在现实临床实践中进行了前瞻性随访5年。使用天冬氨酸转氨酶 - 血小板比指数（APRI）测定纤维化期。终点是肝硬化，肝癌或死亡。用HepG2，HLE，PLC和SMMC-7721细胞中油酸诱导的脂质积累研究脂肪变性对肝细胞癌细胞生物学行为的影响。
结果：

CHB患者的平均年龄，体重指数和血清胆固醇明显高于基线时无HS组（P <0.05）。基线时无AP的患者APRI较低（p <0.05）。与HS患者相比，随访期间无HS患者APRI明显降低（p <0.05）。肝硬化5年累积发生率分别为4.17％和5.19％（P> 0.05）。多因素分析显示，老年人（RR 1.07,95％CI 0.996-1.149，p = 0.065）和S3期肝纤维化（RR 3.50,95％CI 0.812-15.117，p = 0.093）是进展为肝硬化的危险因素。在体外，细胞脂肪变性促进HCC细胞的增殖和迁移，并在S期赋予细胞周期。
结论：

老年和S3期纤维化可能是HSB患者进展为肝硬化的危险因素。 HS可能加重肝脏疾病，促进HCC进展。
关键词：

慢性乙型肝炎肝脂肪变性肝细胞癌细胞

结论：
    28500841
DOI：
    10.18632 / oncotarget.17380

免费全文

StephenW

http://www.impactjournals.com/on ... mp;path%5B%5D=55606